spartalizumab for Breast Cancer

"Spartalizumab's safety ranking on a scale of 1 to 3 is 1, due to it being in Phase I trials and the lack of data supporting its efficacy."

"Research into spartalizumab began in 2011 with an initial trial sponsored by Novartis Pharmaceuticals. This first study had 185 participants, and it led to the drug's Phase 1 approval. There are currently 52 active studies for spartalizumab spread across 352 cities and 54 countries."

"Unfortunately, this trial is not accepting any new patients at present. Initially posted on January 31st 2019, the study has been recently modified as of November 18th 2022. At the moment there are 2351 trials for breast cancer and 52 studies using spartalizumab that are actively enrolling participants if you wish to explore other options."

"Spartalizumab is most commonly prescribed to treat neonatal-onset multisystem inflammatory disease (nomid). Additionally, it can be utilized for familial cold autoinflammatory syndrome (fcas), muckle-wells syndrome (mws), and active systemic juvenile idiopathic arthritis."

"As found on clinicaltrials.gov, the trial is not presently looking for participants. First posted in January of 2019 and last updated November 18th 2022, there are no more recruitment efforts taking place at this time; however, 2403 other studies are still enrolling patients."

"Currently, there are 52 studies being conducted on spartalizumab. Out of those trials, 7 have reached Phase 3 and further 1364 medical centres across the country are participating in this research. Notably, many of these sites are located within New york City itself."